Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Investors are betting on mitral valves as the next "big thing" in cardiology as interest in technologies to treat mitral regurgitation heat up among the big heart players. Competition among the developers of transcatheter mitral valve repair systems is intensifying as they jostle for attention, but start-up Kephalios believes the simplicity of its technology, which precisely targets repair of the defective valve, will help it stand out.
Check out what Saluda Medical President Dan Bournstein had to say about the firm's responsive, closed-loop spinal cord stimulation technology for which it is seeking CE mark this year and FDA approval by 2020.
Start-Up Spotlight: Saluda Hopes To 'Evoke' From Down Under With First Closed-Loop Spine-Stim System
Aiming to improve the lives of patients living with chronic, intractable pain, Australian start-up Saluda Medical Pty Limited is the first and only neuromodulation company in the world to develop a closed-loop spinal cord stimulation system (SCS). Unlike other SCS systems marketed today, Saluda’s device, currently in clinical trials, is designed to measure the spinal cord’s response to electrical stimulation, and then respond to patient's preferred stimulation.
EpicHeart by CorInnova is an advanced cardiac compression device that combines the advantages of a flexible endoskeleton and soft robotics to provide biventricular cardiac support for heart-failure patients. Because the device does not touch the blood, many adverse events such as stroke and gastrointestinal bleeding associated with existing cardiac-assist technologies are eliminated. Delivered minimally invasively, the potential patient population is also much larger than for a chronic left ventricular assist device.
Israeli start-up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.
Bioelectronics company Thync is gearing up for more clinical trials in 2018 to demonstrate the benefits of its neuromodulation platform for treating psoriasis. The Silicon Valley startup currently sells its wearable device to treat anxiety, stress and improve sleep.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.